Developing core technology of silk fibroin protein and breaking through innovation barriers in the field of silk application, Xingyue Biotechnology was awarded the "Innovation Star"

Another year of spring grass green, still ten miles of apricot blossoms red. On March 28, 2024, the "2023 Hangzhou Yuhang District Biomedical Industry Association Annual Meeting and Third Member Conference" was held grandly in Hangzhou Future Science and Technology City. Zhao Hongshi, Executive Vice General Manager of Zhejiang Xingyue Biotechnology Co., Ltd., and Yu Jinyou, Office Director, attended the conference on behalf of the company.

In the past year of 2023, Xingyue Biotechnology has achieved outstanding results in the research and registration of "medical silk fibroin" medical devices, and has won the "Innovation Star" award in the biopharmaceutical and medical device industry of Yuhang District in 2023. The achievement of this honor is not only a recognition of Xingyue Biotechnology's research and development capabilities in the field of medical devices, but also an encouragement and expectation for Xingyue Biotechnology's future development.

The Yuhang District Biopharmaceutical Industry Association is an important carrier and link for the development and exchange of the biopharmaceutical industry, gathering multiple outstanding enterprises engaged in innovative drugs, medical devices, health services and other industries in Yuhang District, fully connecting the upstream and downstream industrial chains, and synergistically supporting the vigorous development of the biopharmaceutical industry.

In recent years, Xingyue Biotechnology has been based on multiple innovative platforms such as Zhejiang Key Enterprise Research Institute and Zhejiang Key Laboratory, relying on independent research and development, continuously promoting and leading the development of the biomedical silk industry, and continuously launching a series of milestone innovative achievements in the medical field of medical silk materials. The world's first multi center clinically validated silk material hernia repair product, recently developed, has been approved for market and highly recognized by the government, industry, and clinical hospitals.

In the future, Xingyue Biotechnology will strengthen cooperation and communication with numerous innovative and high-quality enterprises within the association, jointly explore the development of the medical device industry, steadily improve clinical research capabilities, and develop high-quality silk medical new quality productivity, providing better products and services for medical institutions, medical workers, and patients.